Original reporting and analysis on the stories shaping biotech.
An FDA advisory panel just voted 7-2 that Grail's Galleri blood test, which screens for 17 cancer types from a single draw, is worth the risks. No lives-saved data yet, but the first-ever multi-cancer screening approval is now closer than ever.
The EU just passed its biggest agricultural biotech reform in two decades, creating a fast lane for certain gene-edited crops. It's a seismic shift for an industry that had all but written off Europe.
Flagship Pioneering, the biotech venture firm behind Moderna, just landed a $47 million Pentagon contract to develop biological threat countermeasures. It's not buying a single drug; the DoD wants access to Flagship's entire ecosystem of 40+ companies, and it signals a new era of biotech as national security infrastructure.
Enveda Biosciences just raised $311 million to let AI decode plant and microbial chemistry into actual drugs. With three candidates already in human trials and a $2 billion valuation, it's one of the year's biggest bets that nature might out-engineer Big Pharma.
Kyverna's CAR-T therapy miv-cel just posted one-year data in stiff person syndrome and myasthenia gravis with durable responses and zero high-grade toxicities. While competitors pause trials after patient deaths and safety scares, Kyverna's clean profile could make it the first approved therapy for SPS.
Trump's FDA nominee Heidi Overton faced senators on Capitol Hill, and the biotech industry is watching nervously. With no agency management experience, a skeptical committee chair, and flashpoint issues from vaccines to abortion pills, her path to confirmation is anything but guaranteed.
Merck's WINREVAIR just added Phase 3 HYPERION data to its FDA label, showing a 76% reduction in clinical worsening for recently diagnosed PAH patients. The first-in-class drug already hit $1.4 billion in sales last year, and the blockbuster math is only getting louder.
For decades, Sjögren's disease had zero FDA-approved treatments that target the actual disease. Amgen's dazodalibep just delivered a clean Phase 3 win in 651 patients, and the race to build an entirely new market is officially on.
Celldex's barzolvolimab swept both Phase 3 trials for chronic hives with striking complete response rates. But two anaphylaxis cases and a neutropenia signal sent shares tumbling 11.6%, and now the market is debating whether it overreacted.
Ulefnersen just delivered the strongest clinical data ever seen in FUS-ALS, a rare and brutal genetic form of Lou Gehrig's disease. The Phase 3 results could reshape how we think about treating neurodegeneration, one gene at a time.
Immunovant's IMVT-1402 just failed its Phase 2 test in cutaneous lupus, and the company killed the program entirely. The setback reveals a growing truth about FcRn inhibitors: they're master keys that only fit certain locks.
HHS just dropped $88 million and 20+ federal initiatives to move drug development away from animal testing and toward AI, organoids, and organ-on-a-chip systems. The lab mice might want to start networking.
Novartis just committed up to $900 million for a preclinical radioligand therapy from China's Boomray Pharmaceuticals, and nobody even knows what the drug targets. With Big Pharma's radioligand arms race heating up and geopolitical tensions simmering, this mystery deal says a lot about where oncology is headed.
Sarepta just added a black box warning to its only approved gene therapy while cutting a third of its workforce. The company that was supposed to prove gene therapy could go mainstream is now fighting for survival at $20 a share.
Novartis's $12 billion acquisition of Avidity Biosciences was supposed to unlock a revolutionary drug platform. Two clinical trial failures later, analysts are questioning the deal, the technology, and the future of pharma's acquisition playbook.
The Trump administration is reportedly drafting an executive order that would let political appointees veto NIH grants. The proposal could fundamentally reshape how America funds the science behind drug discovery, and biotech has every reason to worry.
Novartis just signed a deal worth up to $3.22 billion with South Korea's Alteogen for technology that converts IV drugs into quick under-the-skin injections. It's one of the biggest drug delivery licensing agreements ever, and it puts a little-known Korean biotech at the center of pharma's convenience revolution.
Novo Nordisk's CagriSema just beat Eli Lilly's tirzepatide on weight loss in a head-to-head Phase 3 trial, delivering 12.4% weight loss versus 9.1% in patients with diabetes. With Lilly controlling over 60% of the U.S. market, this changes everything about the obesity drug arms race.
Roche's Phase II obesity and diabetes data on enicepatide just turned heads, with 22.5% weight loss in obesity patients and blood sugar normalization rates that rival the best in class. The $2.7 billion Carmot acquisition is looking smarter by the month, and the Lilly-Novo duopoly is officially on notice.
FDA staff reviewers found no major concerns about Grail's Galleri multi-cancer blood test, sending the stock up 35% ahead of a landmark advisory committee vote. Tomorrow's meeting could set the regulatory template for the entire liquid biopsy screening category.
Iambic Therapeutics, backed by Nvidia and Qatar's sovereign wealth fund, just filed for a $100 million Nasdaq IPO. With one cancer drug in trials and an AI platform that designs molecules in a loop, it's the latest test of whether Wall Street will buy the AI drug discovery dream.
China just set a stunning target: develop 25% of the world's first-in-class drugs by 2030. With approvals already doubling in two years and $120 billion in licensing deals flowing, the country's leap from fast-follower to innovation leader could reshape global pharma competition.
Join thousands of biotech professionals who start their day with our free, daily briefing.